secwatch.observer — SEC 8-K summary
======================================

Issuer:     Canton Strategic Holdings, Inc. (CNTN)
CIK:        0001861657
Form:       8-K
Filed at:   2024-09-30T23:59:59+00:00
Accession:  0001493152-24-038730
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tharimmune signs nonbinding LOI to merge with Intract Pharma; 49% stake for Intract shareholders
--------------------------------------------------------------------------------

- Tharimmune and Intract Pharma entered nonbinding LOI; Tharimmune to acquire Intract for restricted stock.
- Intract shareholders will own 49% of combined entity; merger expected to close in Q1 2025.
- Combined company will leverage Intract's Soteria and Phloral oral delivery platforms for biologics.
- Existing license for oral anti-TNF antibody (INT-023/TH023) from Intract remains unaffected.
- Transaction aims to expand Tharimmune's pipeline in inflammation and immunology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861657/000149315224038730/0001493152-24-038730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861657/000149315224038730/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-038730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer